Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as ...

BERLIN – German drug maker Merck KGaA announced Sunday that it is selling its generic drug business to Mylan Laboratories Inc. of the U.S. for $6.6 billion. The deal frees Darmstadt-based Merck to ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the ...

This morning Merck took a difficult and necessary step in trying to wring cost savings out of its $41 billion purchase of Schering-Plough: closing research labs and manufacturing plants. Such closures ...

NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

Initiative combines Merck's drug development expertise with Flagship's experience in building early stage companies CAMBRIDGE, Mass., Apr 10, 2012 (BUSINESS WIRE) -- Flagship Ventures, a leading ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Merck Research Laboratories (MRL) facilities in Rahway, N.J., and West ...

When rumors started swirling late last week that Roger Perlmutter, newly appointed Merck research chief, had started cleaning house, industry observers saw it as the proverbial shoe dropping.

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey BENGALURU (Reuters) - Shares of ...

In work on a tumor-cell inhibitor, chemists in Merck’s technology enabled synthesis (TES) group in West Point, Pa., found that microwave chemistry—they use Biotage instruments—has not only sped up ...

FRANKFURT (Reuters) - German drugs and chemicals maker Merck KGaA has raised its full-year core earnings forecast in response to strong demand for its lab supplies and on the back of its $17 billion ...

Merck KGaA’s fair value price target has been reset to €141.27 from €143.20, a modest reduction of about 1.4% that keeps the stock in a similar valuation zone. This adjustment aligns with a wave of ...